Haileyesus Getahun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Haileyesus Getahun has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Mario Raviglione
Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy
8 shared publications Alberto Matteelli
From World Health Organization Global TB Programme, Geneva, Switzerland, and University of Brescia, Brescia, Italy
4 shared publicationsChristian Gunneberg
4 shared publicationsPaul Nunn
4 shared publicationsAnnabel Baddeley
Global TB Programme, World Health Organization, Geneva, Switzerland
3 shared publicationsDelphine Sculier
3 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 1 July 2020
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 98 (7) , 442-442A
Tackling antimicrobial resistance in the COVID-19 pandemic
- 1 July 2020
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 98 (7) , 442-442A
Top Cited PapersOpen AccessTackling antimicrobial resistance in the COVID-19 pandemic
- 1 November 2018
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 13 (6) , 538-542
Identifying priorities for HIV-associated tuberculosis research through the WHO guidelines process
Guidelines developed by the WHO aim to provide recommendations to support best practice in health delivery, with a focus on low-income and middle-income countries. As part of the guideline development process, critical knowledge gaps are identified and one of the core functions of WHO guidelines is to set forth priorities for future research. A review of research priorities identified through the WHO guideline development has recently been promoted as one approach to building an overarching priority research agenda in a given area. This paper outlines priorities for HIV-associated TB research identified in WHO HIV and TB guidelines published since 2015. Nine guidelines were reviewed and 29 priority research questions were identified. Research priorities were identified for prevention of HIV-associated TB (11 questions), screening of latent and active TB in people living with HIV (six questions), treatment of drug sensitive (four questions), and drug-resistant (two questions) TB, and treatment of HIV in people coinfected with TB (three questions). Multiple approaches to defining priority research questions for health research exist. Research priorities that arise from the WHO guideline development process are limited to those areas for which guidelines are developed. One strength of this approach is that it takes as a starting point a desire to make actionable recommendations for policy makers. WHO is working to further refine the formulation of research questions within the guideline development process.
- 1 November 2018
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 13 (6) , 538-542
Identifying priorities for HIV-associated tuberculosis research through the WHO guidelines process
Guidelines developed by the WHO aim to provide recommendations to support best practice in health delivery, with a focus on low-income and middle-income countries. As part of the guideline development process, critical knowledge gaps are identified and one of the core functions of WHO guidelines is to set forth priorities for future research. A review of research priorities identified through the WHO guideline development has recently been promoted as one approach to building an overarching priority research agenda in a given area. This paper outlines priorities for HIV-associated TB research identified in WHO HIV and TB guidelines published since 2015. Nine guidelines were reviewed and 29 priority research questions were identified. Research priorities were identified for prevention of HIV-associated TB (11 questions), screening of latent and active TB in people living with HIV (six questions), treatment of drug sensitive (four questions), and drug-resistant (two questions) TB, and treatment of HIV in people coinfected with TB (three questions). Multiple approaches to defining priority research questions for health research exist. Research priorities that arise from the WHO guideline development process are limited to those areas for which guidelines are developed. One strength of this approach is that it takes as a starting point a desire to make actionable recommendations for policy makers. WHO is working to further refine the formulation of research questions within the guideline development process.
- 21 November 2017
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 167 (10) , 742-743
Tailoring Treatment of Latent Tuberculosis to the Needs of Patients and Families
- 21 November 2017
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 167 (10) , 742-743
Tailoring Treatment of Latent Tuberculosis to the Needs of Patients and Families
- Open Access
- 1 January 2017
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 20 (1) , 50-56
Epidemiology of HIV-associated tuberculosis in Eastern European countries and the Russian Federation in 2004—2014: A review of lite-rature
Medical article медицинская статья
- 1 January 2017
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 20 (1) , 50-56
Open AccessEpidemiology of HIV-associated tuberculosis in Eastern European countries and the Russian Federation in 2004—2014: A review of lite-rature
Medical article медицинская статья
- 30 April 2016
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 47 (5) , 1327-1330
Advancing global programmatic management of latent tuberculosis infection for at risk populations
Intensification of #LTBI treatment for child #TB contacts and people living with #HIV and other at risk populationshttp://ow.ly/ZfzAv
- 30 April 2016
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 47 (5) , 1327-1330
Advancing global programmatic management of latent tuberculosis infection for at risk populations
Intensification of #LTBI treatment for child #TB contacts and people living with #HIV and other at risk populationshttp://ow.ly/ZfzAv
- Top Cited PapersOpen Access
- 24 September 2015
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 46 (6) , 1563-1576
Management of latentMycobacterium tuberculosisinfection: WHO guidelines for low tuberculosis burden countries
Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses to previously acquiredMycobacterium tuberculosisinfection without clinical evidence of active tuberculosis (TB). Here we report evidence-based guidelines from the World Health Organization for a public health approach to the management of LTBI in high risk individuals in countries with high or middle upper income and TB incidence of <100 per 100 000 per year. The guidelines strongly recommend systematic testing and treatment of LTBI in people living with HIV, adult and child contacts of pulmonary TB cases, patients initiating anti-tumour necrosis factor treatment, patients receiving dialysis, patients preparing for organ or haematological transplantation, and patients with silicosis. In prisoners, healthcare workers, immigrants from high TB burden countries, homeless persons and illicit drug users, systematic testing and treatment of LTBI is conditionally recommended, according to TB epidemiology and resource availability. Either commercial interferon-gamma release assays or Mantoux tuberculin skin testing could be used to test for LTBI. Chest radiography should be performed before LTBI treatment to rule out active TB disease. Recommended treatment regimens for LTBI include: 6 or 9 month isoniazid; 12 week rifapentine plus isoniazid; 3–4 month isoniazid plus rifampicin; or 3–4 month rifampicin alone.
- 24 September 2015
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 46 (6) , 1563-1576
Top Cited PapersOpen AccessManagement of latentMycobacterium tuberculosisinfection: WHO guidelines for low tuberculosis burden countries
Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses to previously acquiredMycobacterium tuberculosisinfection without clinical evidence of active tuberculosis (TB). Here we report evidence-based guidelines from the World Health Organization for a public health approach to the management of LTBI in high risk individuals in countries with high or middle upper income and TB incidence of <100 per 100 000 per year. The guidelines strongly recommend systematic testing and treatment of LTBI in people living with HIV, adult and child contacts of pulmonary TB cases, patients initiating anti-tumour necrosis factor treatment, patients receiving dialysis, patients preparing for organ or haematological transplantation, and patients with silicosis. In prisoners, healthcare workers, immigrants from high TB burden countries, homeless persons and illicit drug users, systematic testing and treatment of LTBI is conditionally recommended, according to TB epidemiology and resource availability. Either commercial interferon-gamma release assays or Mantoux tuberculin skin testing could be used to test for LTBI. Chest radiography should be performed before LTBI treatment to rule out active TB disease. Recommended treatment regimens for LTBI include: 6 or 9 month isoniazid; 12 week rifapentine plus isoniazid; 3–4 month isoniazid plus rifampicin; or 3–4 month rifampicin alone.
- Open Access
- 1 June 2015
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 19 (6) , 623-4
Transitioning from 'stopping' to 'ending' the tuberculosis epidemic.
- 1 June 2015
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 19 (6) , 623-4
Open AccessTransitioning from 'stopping' to 'ending' the tuberculosis epidemic.
- Top Cited Papers
- 28 May 2015
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 372 (22) , 2127-2135
LatentMycobacterium tuberculosisInfection
About one third of the world population has latent M. tuberculosis infection. This review explains the approach to patients with latent infection, including an update on the risks and benefits of treatment and assessment of the likelihood of progression to active disease.
- 28 May 2015
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 372 (22) , 2127-2135
Top Cited PapersLatentMycobacterium tuberculosisInfection
About one third of the world population has latent M. tuberculosis infection. This review explains the approach to patients with latent infection, including an update on the risks and benefits of treatment and assessment of the likelihood of progression to active disease.
- 1 October 2013
- Published by Elsevier in The Lancet
- Vol. 382 (9899) , 1157-9
Household tuberculosis interventions--how confident are we?
- 1 October 2013
- Published by Elsevier in The Lancet
- Vol. 382 (9899) , 1157-9
Household tuberculosis interventions--how confident are we?